Transdermal buprenorphine in the treatment of cancer and non-cancer pain - The results of multicenter studies in Poland

Pharmacological Reports

Volumn 63, Issue 4, 2011, Pages 935-948

  Przeklasa Muszyńska, Anna ^a   Dobrogowski, Jan ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Cancer pain; Non cancer pain; Safety; Transdermal buprenorphine; Transtec

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ANALGESIC AGENT; ANTIEMETIC AGENT; BUPRENORPHINE; CARBAMAZEPINE; CLODRONIC ACID; CODEINE PLUS PARACETAMOL; DEXAMETHASONE; DICLOFENAC; DIPYRONE; DOCUSATE SODIUM; GABAPENTIN; IBUPROFEN; KETOPROFEN; LACTULOSE; LAMOTRIGINE; LAXATIVE; LORAZEPAM; MELOXICAM; METOCLOPRAMIDE; MORPHINE; NIMESULIDE; PARACETAMOL; PARACETAMOL PLUS TRAMADOL; TIANEPTINE; TRAMADOL; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; ARTICLE; CANCER PAIN; CHRONIC PAIN; CONFUSION; CONSTIPATION; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; ERYTHEMA; FEMALE; FOLLOW UP; GENERALIZED ERYTHEMA; HUMAN; HYPERHIDROSIS; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL PAIN; NAUSEA; NEUROPATHIC PAIN; PAIN; PAIN ASSESSMENT; PATIENT SATISFACTION; POLAND; POSTMARKETING SURVEILLANCE; PRURITUS; QUALITY OF LIFE; SLEEP QUALITY; SOMNOLENCE; VISUAL ANALOG SCALE; VOMITING;

EID: 80053353326     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70609-0     Document Type: Article

References (31)

1. Böhme K, Likar R: Efficacy and tolerability of a new opioid analgesic formulation, buprenorphine transdermal therapeutic system (TDS), in the treatment of patients with chronic pain. A randomised, double-blind, placebo-controlled study. Pain Clinic, 2003, 15-19.
2. Budd K, Raffa RB: Buprenorphine the Unique Opioid Analgesic. Stuttgart, Germany, Thieme Publishers, Stuttgart, 2005.
3. Camba MA, Rodríguez-López MJ, Muriel C, Grupo de Studio de Opioides de la Socieda Española del Dolor: Buprenorphine TDS in the treatment of chronic nociceptive, neuropathic and cancer-related pain. J App Ther Res, 2007, 6, 3-13.
4. Ciałkowska-Rysz A, Kaźmierczak-Łukaszewicz S, Gottwald L: The use of transdermal buprenorphine in chronic cancer pain treatment (Polish). Medycyna Paliatywna, 2009, 1, 40-44.
5. Cowan A, Doxey JC, Harry EJ: The animal pharmacology of buprenorphine, an oripavine analgesic agent. Br J Pharmacol, 1977, 60, 547-554. (Pubitemid 8149540)
6. Dahan A, Yassen A, Bijl H, Romberg R, Sarton E, Teppema L, Olofsen E, Danhof M: Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth, 2005, 94, 825-834. (Pubitemid 40754001)
7. Dertwinkel R, Donner B, Zenz M, Schulz S, Bading B: Opioids in chronic pain. Baillière's Clinical Anaesthesiology, 1998, 39-52. (Pubitemid 28454412)
8. Eisenberg E, Marinangeli F, Birkhahn J, Paladini A, Varrassi G: Time to modify the WHO Analgesic Ladder? Pain Clinical Updates, 2005, 13, 1-4.
9. Faymonville ME, Libbrecht D: Transdermal buprenorphine: a current overview of pharmacological and clinical data. Rev Med Liege, 2008, 63, 671-676.
10. Giardina V, Invernizzi A, Baiardi P, Radaelli S, Miotti D: Randomized pilot study to control the cancer pain by administering transdermally fentanyl or buprenorphine (Italian). La rivista italiana di cure palliative, 2005, 5, 30-35.
11. Gonzalez-Escalada JR: The Opioid Study Group of the Spanish Pain Society: Use of buprenorphine and oral morphine in patient with chronic pain. Rev Soc Esp Dolor, 2004, 3-10.
12. Gordon A, Rashiq S, Moulin DE, Clark AJ, Beaulieu AD, Eisenhoffer J, Piraino PS et al.: Buprenorphine transdermal system for opioid therapy in patients with chronic low back pain. Pain Res Manag, 2010, 15, 169-178.
13. Griessinger N, Sittl R, Likar R: Transdermal buprenorphine in clinical practice-a post-marketing surveillance study in 13179 patients. Curr Med Res Opin, 2005, 21, 1147-1156. (Pubitemid 41140716)
14. Huang P, Kehner GB, Cowan A, Liu-Chen LY: Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther, 2001, 297, 688-695. (Pubitemid 32378001)
15. Kress H: Buprenorphine in Patients with Increased Vulnerability to Potential Opioid Adverse Effects. Thieme Verlag, Stuttgart, 2005.
16. Leppert W: Role of oxycodone and oxycodone/naloxone in cancer pain management. Pharmacol Rep, 2010, 62, 578-591.
17. Likar R, Kayser H, Sittl R: Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials. Clin Ther, 2006, 28, 943-952. (Pubitemid 44062699)
18. Mercadante S: Opioid titration in cancer pain: a critical review. Eur J Pain, 2007, 11, 823-830.
19. Muriel C, Failde I, Micó JA, Neira M, Sánchez-Magro I: Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study. Clin Ther, 2005, 27, 451-462. (Pubitemid 40732652)
20. Muriel C, Villoria C, Perez-Castejon Garotte JM, Sanchez Magro I, Neira Alvarez I: Effectiveness and safety of transdermal buprenorphine for chronic pain treatment in the elderly: a prospective observational study. Med Clin, 2007, 128, 204-210. (Pubitemid 46382310)
21. Pace MC, Passavanti MB, Grella E, Mazzariello L, Maisto M, Barbarisi M, Baccari E et al.: Buprenorphine in long term control of chronic pain in cancer patients. Front Biosci, 2007, 1, 1291-1299. (Pubitemid 46846834)
22. Pergolizzi J, Aloisi AM, Dahan A, Filitz J, Langford R, Likar R, Mercadante S et al.: Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract, 2010.
23. Pergolizzi JV, Mercadante S, Echaburu AV, van den Eynden B, Fragoso RM, Mordarski S, Lybaert Wet al.: The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus. Curr Med Res Opin, 2009, 25, 1517-1528.
24. Radbruch L, Sabatowski R, Petzke F, Brunsch-Radbruch A, Grond S, Lehmann KA: Transdermal fentanyl for the management of cancer pain: a survey of 1005 patients. Palliat Med, 2001, 15, 309-321. (Pubitemid 32640549)
25. Schmitz S, Bruch HR, Hagen-Aukamp C: Transdermal buprenorphine in patients with cancer-related pain in oncological practice. J Appl Ther Res, 2008, 6, 20-31.
26. Sittl R, Griessinger N, Likar R: Analgesic efficacy and tolerability of transdermal buprenorphine in patients within adequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double blind, placebo controlled trial. Clin Ther, 2003, 25, 150-168. (Pubitemid 36206743)
27. Sittl R: Transdermal buprenorphine in cancer pain and palliative care. Palliat Med, 2006, 20, 25-30.
28. Sorge J, Sittl R: Transdermal buprenorphine in the treatment of chronic pain. Results from a phase III, multicenter, randomized, double-blind, placebo controlled study. Clin Ther, 2004, 26, 1808-1820. (Pubitemid 40089494)
29. Transtec: Summary of Product Characteristics. Ministry of Health in Poland, 22. 08. 2007.
30. Vadivelu N, Hines RL: Management of chronic pain in the elderly: focus on transdermal buprenorphine. Clin Interv Aging, 2008, 3, 421-430.
31. nd edn., Geneva, 1995.